Operative mortality fell over time, but there was a concerning uptick in recent years attributed to low-volume sites.

There was a consensus that more data are needed to answer this question, with discussions about what such a trial would look ...

Outcomes and expenses were similar with transplant and elective LVAD, but urgent LVAD after ECMO fared much worse.

PE or PEERLESS, the choice of therapy was shifting, influenced by patient factors and institutional protocols.

Even as BAT expands beyond trial criteria, patients see gains in LVEF, symptoms, and more. A survival impact remains unclear.

Patients already had high NT-proBNP levels at baseline, though, raising questions about the quality of GDMT, Nancy Sweitzer ...

More inclusive research on bleeding could enable better care for medically managed patients, not just those who get PCI.

The findings suggest clinicians don’t need to be as aggressive in lowering BP in this population, at least early after ...

The study emphasizes the importance of vigilance with diet and exercise, among other things, to reduce CV risk in type 2 diabetes.

Amid late-breaking coronary, structural, and endovascular trials will be a keynote from President Biden, and more.

Daniel Burkhoff and Akshay Desai discuss the innovative technologies and late-breaking science presented at day 2 of THT.

The approach could help clinicians who are “burdened with information overload” manage their patients, one expert says.